Boston Docs Study Promising New Alzheimer's Drug

BOSTON (WBZ) ―

Alzheimer's May Affect Patients' Memory Earlier (2/19/2009)
Massachusetts researchers are looking for patients to test a promising new Alzheimer's drug. Experts believe it could be the first drug to actually slow down the disease.

Irene Courchesne was diagnosed with early symptoms of Alzheimer's three years ago. "Things started to get really funny," Irene said. "I couldn't remember. I used to have to go to court and I couldn't get my stuff correct."

That's why Irene decided to take part in a new clinical trial being done at the Boston University School of Medicine.

Researchers at B.U. are testing a promising new drug which they believe can actually slow down the progression of Alzheimer's, instead of just temporarily treating the symptoms like current treatments.

Dr. Robert Stern, co-director of the Alzheimer's disease Clinical and Research Program at the B.U. School of Medicine explains, "This new drug has as its goal the ability to suck out the amyloid proteins from the brain which we think is the cause of Alzheimer's and will dramatically alter the course of Alzheimer's disease."

Irene Courchesne, who enrolled in the study in December, says she started to notice....read the whole article

For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here

Ground-breaking anti-amnesic and neuroprotective effects of Alzheimer's compound ANAVEX 1-41 published in Journal of Neuropsychopharmacology

ATHENS, GREECE,PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition of Neuropsychopharmacology. Currently in the late pre-clinical stage, ANAVEX 1-41 is one of the company's lead compounds for Alzheimer's disease (AD). Neuropsychopharmacology is an international scientific journal and the official publication of the American College of Neuropsychopharmacology, which focuses on clinical and basic science contributions that advance our understanding of the brain and behaviour.

"The ANAVEX 1-41 results highlighted in this important paper clearly demonstrate the compound's efficacy, which can be attained at extremely.......read the whole article

For more information on dementia, click here

If you are interested in dementia activities, click here